Kovitz Investment Group Partners LLC Sells 4,031 Shares of Insulet Corporation $PODD

Posted by Stanley Muller on Jun 20th, 2026

Kovitz Investment Group Partners LLC trimmed its position in Insulet Corporation (NASDAQ:PODD – Free Report) by 27.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 10,672 shares of the medical instruments supplier’s stock after selling 4,031 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Insulet were worth $3,034,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its position in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Insulet during the 4th quarter worth approximately $26,000. DV Equities LLC bought a new stake in shares of Insulet during the fourth quarter worth approximately $28,000. Elyxium Wealth LLC bought a new stake in shares of Insulet during the fourth quarter worth approximately $28,000. Finally, Mcguire Capital Advisors Inc. bought a new stake in shares of Insulet during the fourth quarter worth approximately $29,000.

Insulet Price Performance

Insulet stock opened at $145.76 on Friday. The stock has a market capitalization of $10.10 billion, a PE ratio of 33.90, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The company has a 50 day moving average of $164.18 and a 200-day moving average of $226.26.

Insulet (NASDAQ:PODD – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period last year, the business posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts anticipate that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Analyst Ratings Changes

PODD has been the topic of a number of recent research reports. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $280.00 price objective on shares of Insulet in a research note on Wednesday, May 27th. Weiss Ratings cut shares of Insulet from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Barclays cut their price target on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research note on Thursday, May 7th. Canaccord Genuity Group reduced their price target on Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Finally, William Blair assumed coverage on Insulet in a research note on Wednesday, May 20th. They set an “outperform” rating for the company. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and a consensus price target of $240.78.

Get Our Latest Report on PODD

Insider Transactions at Insulet

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.36% of the company’s stock.

Insulet Profile

(Free Report)

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.